Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?

Int J Gynecol Cancer · 2023 · PMC10646884 · PMID 37640446

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendp=0.09so close (0.05 < p ≤ 0.1)

27 In the same report, patients with low-grade cancer showed a trend toward lower estimated odds of response to chemotherapy compared with those with high-grade disease (p=0.09). 27 More recently, carboplatin/paclitaxel was established as standard of care by GOG 209.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.